Should I buy or sell Kezar Life Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KZR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZR, but not buy additional shares or sell existing shares. View KZR analyst ratings or view top-rated stocks .

What is Kezar Life Sciences' stock price target for 2024?

3 analysts have issued 1-year price objectives for Kezar Life Sciences' stock. Their KZR share price targets range from $2.00 to $20.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,247.0% from the stock's current price. View analysts price targets for KZR or view top-rated stocks among Wall Street analysts .

How have KZR shares performed in 2024?

Kezar Life Sciences' stock was trading at $0.9474 at the beginning of the year. Since then, KZR stock has decreased by 13.8% and is now trading at $0.8166. View the best growth stocks for 2024 here .

Are investors shorting Kezar Life Sciences?

Kezar Life Sciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,570,000 shares, an increase of 5.6% from the March 15th total of 3,380,000 shares. Based on an average daily volume of 717,500 shares, the short-interest ratio is currently 5.0 days. View Kezar Life Sciences' Short Interest .

When is Kezar Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KZR earnings forecast .

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04.

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV) , OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , Pfizer (PFE) , VYNE Therapeutics (vyne) , Dynavax Technologies (DVAX) , Gilead Sciences (GILD) , AbbVie (ABBV) , Aldeyra Therapeutics (ALDX) and Exelixis (EXEL) .

When did Kezar Life Sciences IPO?

Kezar Life Sciences (KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free KZR Stock Alerts

$0.82

+0.03 (+3.81%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.77
▼
$0.82
50-Day Range: $0.78
▼
$1.05
52-Week Range: $0.67
▼
$3.13

Volume: 446,769 shs
Average Volume: 705,687 shs
Market Capitalization: $59.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get Kezar Life Sciences alerts:

Kezar Life Sciences MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 1,247.0% Upside
$11.00 Price Target
Short Interest: Bearish
4.90% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.56
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.26) to ($1.25) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.05 out of 5 stars

Medical Sector

168th out of 914 stocks

Pharmaceutical Preparations Industry

58th out of 404 stocks

3.2

Analyst's Opinion

Consensus Rating
Kezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Kezar Life Sciences has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.90% of the outstanding shares of Kezar Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Kezar Life Sciences has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Kezar Life Sciences has recently increased by 5.62%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Kezar Life Sciences does not currently pay a dividend.
Dividend Growth
Kezar Life Sciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kezar Life Sciences has received a 73.01% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Kezar Life Sciences is -0.85.

3.1

News and Social Media Coverage

News Sentiment
Kezar Life Sciences has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Kezar Life Sciences this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for KZR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
4 people have added Kezar Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.90% of the stock of Kezar Life Sciences is held by insiders.
Percentage Held by Institutions
67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Kezar Life Sciences are expected to grow in the coming year, from ($1.26) to ($1.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kezar Life Sciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kezar Life Sciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kezar Life Sciences has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Kezar Life Sciences Stock (NASDAQ:KZR)

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

KZR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KZR Stock News Headlines

April 16, 2024 | americanbankingnews.com

Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Up 5.6% in March

April 9, 2024 | americanbankingnews.com

Centessa Pharmaceuticals (NASDAQ:CNTA) vs. Kezar Life Sciences (NASDAQ:KZR) Financial Survey

April 17, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 8, 2024 | businesswire.com

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

March 27, 2024 | investorplace.com

From Pennies to Fortunes: 3 Stocks Set to Make Millionaires

March 16, 2024 | investorplace.com

Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026

March 14, 2024 | investorplace.com

KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023

March 14, 2024 | businesswire.com

Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

April 17, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 12, 2024 | finanznachrichten.de

Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon

March 3, 2024 | finance.yahoo.com

Kezar Life Sciences, Inc. (KZR)

February 28, 2024 | finance.yahoo.com

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

February 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese Market

February 26, 2024 | businesswire.com

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

February 26, 2024 | prnewswire.com

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

February 25, 2024 | investorplace.com

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond

February 22, 2024 | benzinga.com

Kezar Life Sciences Stock (NASDAQ:KZR) Dividends: History, Yield and Dates

February 19, 2024 | thestreet.com

Kezar Life Sciences Inc.

February 10, 2024 | finance.yahoo.com

3 Penny Stocks Poised for an Unbelievable 1,000% Jump

January 31, 2024 | morningstar.com

Kezar Life Sciences Inc KZR

January 18, 2024 | finance.yahoo.com

KZR Jan 2025 17.500 call

December 26, 2023 | finance.yahoo.com

Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth

December 5, 2023 | msn.com

Everest inches towards clinical studies for renal disease drug in China

November 27, 2023 | markets.businessinsider.com

Buy Rating Affirmed: Kezar Life Sciences’ Promising Trials and Strong Financials

November 27, 2023 | markets.businessinsider.com

Analyst Expectations for Kezar Life Sciences's Future

November 21, 2023 | finance.yahoo.com

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

November 14, 2023 | benzinga.com

Kezar Life Sciences Stock (NASDAQ:KZR), Analyst Ratings, Price Targets, Predictions

See More Headlines

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KZR
CUSIP: N/A
CIK: 1645666
Web: www.kezarlifesciences.com
Phone: (650) 822-5600
Fax: N/A
Employees: 58
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $20.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +1,292.4%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-101,870,000.00
Net Margins: N/A
Pretax Margin: -1,455.29%
Return on Equity: -43.08%
Return on Assets: -37.59%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 11.66
Quick Ratio: 11.66

Sales & Book Value

Annual Sales: $7 million
Price / Sales: 8.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.58 per share
Price / Book: 0.31

Miscellaneous

Outstanding Shares: 72,800,000
Free Float: 67,050,000
Market Cap: $57.51 million
Optionable: Not Optionable
Beta: 0.47

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Christopher J. Kirk Ph.D. (Age 51)
Co-Founder, CEO & Director
Comp: $677.41k
Mr. John Franklin Fowler (Age 52)
Co-Founder & Director
Comp: $919.91k
Dr. Jack Taunton Ph.D.
Co-Founder
Mr. Marc L. Belsky (Age 69)
CFO & Secretary
Comp: $491.79k
Ms. Gitanjali Jain
Vice President of Investor Relations & External Affairs
Mr. Mark Schiller
Chief Legal Officer
Dr. Neel K. Anand Ph.D.
Senior Vice President of Research & Drug Discovery
Dr. Nick Mordwinkin Ph.D. (Age 43)
Pharm.D., Chief Business Officer & Head of Strategy
Mr. Zung To
Senior Vice President of Clinical Development
Ms. Pattie Chiang
VP & Corporate Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

KZR Stock Analysis - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KZR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZR, but not buy additional shares or sell existing shares.
View KZR analyst ratings or view top-rated stocks.
What is Kezar Life Sciences' stock price target for 2024?: 3 analysts have issued 1-year price objectives for Kezar Life Sciences' stock. Their KZR share price targets range from $2.00 to $20.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,247.0% from the stock's current price.
View analysts price targets for KZR or view top-rated stocks among Wall Street analysts.
How have KZR shares performed in 2024?: Kezar Life Sciences' stock was trading at $0.9474 at the beginning of the year. Since then, KZR stock has decreased by 13.8% and is now trading at $0.8166.
View the best growth stocks for 2024 here.
Are investors shorting Kezar Life Sciences?: Kezar Life Sciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,570,000 shares, an increase of 5.6% from the March 15th total of 3,380,000 shares. Based on an average daily volume of 717,500 shares, the short-interest ratio is currently 5.0 days.
View Kezar Life Sciences' Short Interest.
When is Kezar Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our KZR earnings forecast.

How were Kezar Life Sciences' earnings last quarter?: Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04.
What other stocks do shareholders of Kezar Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).
When did Kezar Life Sciences IPO?: Kezar Life Sciences (KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.
How do I buy shares of Kezar Life Sciences?: Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KZR) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kezar Life Sciences (KZR) Stock Price, News & Analysis

Kezar Life Sciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Kezar Life Sciences Stock (NASDAQ:KZR)

KZR Stock Price History

KZR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

KZR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™